{
  "symbol": "PRAX",
  "company_name": "Praxis Precision Medicines Inc",
  "ir_website": "https://investors.praxismedicines.com/",
  "structured_data": [
    {
      "section_name": "Recent News Releases",
      "links": [
        {
          "title": "Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting",
          "url": "https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-showcase-updates-largest-epilepsy",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Press Release \n\n[PDF Version](/node/9821/pdf)\n\n## \n\nPraxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting\n\nNovember 26, 2024 at 8:00 AM EST\n\nBOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- [_Praxis Precision Medicines_](https://www.globenewswire.com/Tracker?data=lkBT7IEc_M91-phlfBkFHEz9L7sCFRPIzYMXRyJOOv1M2FeT4DGRuAuxjpkT7fbh7XvEdHTo2-kA6CWQtBCxITyIJkpcHEXM_6vTeusCu3k=), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society (AES) Annual Meeting, being held from December 6 to 10, 2024 in Los Angeles, California.\n\n“At Praxis, we are on the brink of transformative change with a leading pipeline that includes relutrigine and vormatrigine, the most potent and most functionally selective anti-seizure medications developed to date,” said Steven Petrou, chief scientific officer and co-founder of Praxis. “Following promising results with the relutrigine EMBOLD study in particularly challenging childhood epilepsies, we are confident that these future therapies will redefine treatment for DEEs as well as focal and generalized epilepsy. This year at AES we will be sharing the latest advances across our epilepsy portfolio through an exciting lineup of activities.”\n\nPraxis will have multiple options for visitors to learn more about its portfolio:\n\n  * _Exhibiting_ at **booth #1235** , where visitors can interact with members of the Praxis team\n  *  _Presenting_ five unique posters covering three of its clinical-stage assets, detailed below\n  *  _Hosting_ a scientific exhibit featuring its leading portfolio of precision epilepsy programs, detailed below\n\n\n\n**Poster Presentations**\n\n  * Saturday December 7, 12:00 p.m. – 2:00 p.m. PST\n  * Location: South Hall H, Level 1\n\n\n\n[**_1.398_**](https://www.globenewswire.com/Tracker?data=C-dA5n60vxK9eeZ9gbmxOFrcjgDeyiazOckH6cPSjnfuFKzHXq35BWQrnpOtgkh_UqaOwRpbknbrKA_tWI1CU_hg106aCX5yiV8cfMR0yjc6lzw-7L8186owr8579i_zvvsdJ_SUN5kuo_nAaxpZvpQkCjSneCHI-xsjazG4yIM=)**.** **Vormatrigine****Demonstrates Potent Antiseizure Activity Across Three Acute Models with Highest Predictive Validity for Focal Onset Seizures**\n\n[**_1.525_**](https://www.globenewswire.com/Tracker?data=L2tr2Og1KgheuiD4DYsvrPI8JrmodUUt8Jhvs35R7oNwevHgkVVTaha5nUCPo2fxK_r31BcNpZuM14niwJpSjlO3uLif3HjGds_0FB2J7I6ZxQSxfqEaAy20zorvJM_AnmiNyMGJn3hPiB738S1G8CIL4cHL_kuNJynYbGjSvnA=)**.** **Emergency Use Case of Relutrigine, a Next-Generation Sodium Channel Functional State Modulator, in an Infant with SCN2A-DEE and Refractory Seizures and Recurrent Status Epilepticus**\n\n[**_1.526_**](https://www.globenewswire.com/Tracker?data=vA9MmUB2gNHMo5Gp5MyNqrDvHM9rJ2AMIO9RyVDgJASCEnKQAplEafi7QBL2nrluF1Rg5vFfI2IQWuG0ajbs46vldO7hDmbUd3TAdutXy2ZI1g_2aoSuLtKIYbUmvWoA_1SURua74YBGMuinXmSdrMH9GGqM5utx7NiURqEcADQ=)**.** **Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy**\n\n[**_1.527_**](https://www.globenewswire.com/Tracker?data=dJVEINq-h6qyKTwzRHBs1eWASqkpeBIsdAXYtAYUKOnz7ZF66ptbr21eVEW927OtvL_UJTCrVBxWjWCKutPQC9PRrlJugodMrBav6zVW_UZluRaAmFVsomcAzws7jYdZPo6WFtSnWHQhDSiL-H2z3WyMe1t4FTEVViy2e4pkr2Y=)**.** **Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework**\n\n[**_1.528_**](https://www.globenewswire.com/Tracker?data=DxFWGwwFZyImqKz8sr0QIPZIsb_I54VhAP0MpU7P00cTj3HWyJ6-6W5K7u7XhJWXu7kKxStB4chABs8ScbE5Tfm2Xi36JU5s7RQvyZq7qgdG030FbJ1YeRnbzBMO-AgD8QHGIKFX3nDm_iNNxZ7akqGfuL5x0EUU83VDn2xMAac=)**.** **Relutrigine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study**\n\nMaterials will be made available on the Resources page of the Praxis website following presentation at AES 2024: [ _https://praxismedicines.com/resources/_](https://www.globenewswire.com/Tracker?data=94hLfU-5NCvx3SjqrKSj1tk1tc5JGLDZ_SOGV0m9WCmj9zj_9zEcg0RhaJ7OoISOCYPmFsimOYkc5LT5qs871uprWwP8on359T0DQA4DLXmrWYYew8V_5xp8dkE2eEsRmzFzVIN2VY02ZbV-gqRfJ1RlIFoPipMgyO5QhSrG6i7O-uNl7g_pAkHKmPFwtsgQkCps334R51o3iUvNoSsd5aj5vrrNgn-lYwcMnPekzJWgsOCbZqd_G_17OLSnFXk-st9ROzWOTY3MU3NgNvSas4YLDQ6ls1TiUMXUPUMMW1eLMq3qNHYhGCs42VY8uuuD6gn_xllSQ8K-grfnhF7jLV4w6Eb4Am1n8prOja0epMc=).\n\n**Scientific Exhibit**\n\n  * [**_Praxis Precision Medicines: Revolutionizing Therapy in Epilepsy_**](https://eppro01.ativ.me/appinfo.php?page=Session&project=AES24&id=SE3MPM24&server=eppro01.ativ.me)\n\n\n  * Monday December 9, 2:00 p.m. – 5:00 p.m. PST\n  * Location: Room 403B, Level 2\n\n\n\n**About Relutrigine (PRAX-562)** Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathies (DEEs) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in severe DEEs. Relutrigine’s mechanism of precision sodium channel (NaV) modulation is consistent with superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel modulation. Data from the Phase 2 EMBOLD study demonstrated in a heavily pre-treated population a well-tolerated, robust, short- and long-term improvement in motor seizures alongside maintained seizure freedom in some patients with SCN2A- and SCN8A-DEE. Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMBOLD study, please visit [_https://www.emboldstudy.com/_](https://www.globenewswire.com/Tracker?data=94hLfU-5NCvx3SjqrKSj1oc-DQoa2_gTTfx1zoyBW0NVv8oxUebVxIB6J5atZl-aq3tlVoHnvhT6RbRgt7jibjA4AuzXvZCIJYXWvR6HbcPfgkcJ4PX_44Z3vQjh2tFR).\n\n**About Vormatrigine (PRAX-628)** Vormatrigine is a next-generation, functionally selective small molecule targeting the hyperexcitable state of NaV channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset seizures and generalized epilepsy. Preclinical data demonstrates vormatrigine is differentiated from standard of care, with the potential to be best-in-class for focal onset seizures. In vitro, vormatrigine has demonstrated superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of vormatrigine have demonstrated unprecedented potency in the maximal electroshock seizure (MES) model, a highly predictive translational model for efficacy in focal epilepsy. Data from the PRAX-628-101 study demonstrated that vormatrigine can be safely dosed in healthy subjects to greater than 15 times the predicted human equivalent of the rodent MES EC50, a translational indicator that suggests a therapeutic window with unprecedented magnitude relative to approved therapies.\n\n**About Elsunersen (PRAX-222)** Elsunersen is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations. In vitro studies of elsunersen have demonstrated reduction in both SCN2A gene expression and protein levels. In vivo, elsunersen has demonstrated significant, dose-dependent reduction in seizures, improvement in behavioral and locomotor activity and increased survival in SCN2A mouse models. Data from the EMBRAVE study demonstrated well-tolerated, significant and sustained seizure reduction in patients with SCN2A-DEE. Elsunersen has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) from the FDA, and ODD and PRIME designations from the European Medicines Agency (EMA) for the treatment of SCN2A-DEE. The Elsunersen program is ongoing under a collaboration with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), and RogCon, Inc. To learn more about the EMBRAVE study, please visit [_https://www.embravestudy.org/_](https://www.globenewswire.com/Tracker?data=94hLfU-5NCvx3SjqrKSj1pC08XZs0c_cLcqAxXYUfHJ7VEg5w-ngtWLz9hVzpumlzKwQi0xDryevwI55llCHWZgOvxnB5gu4Hqxqs-oTXw6XnT-i0t8Ac_3Pca5MUAwF).\n\n**About Praxis** Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit [ _www.praxismedicines.com_](https://www.globenewswire.com/Tracker?data=-PgyJpgsidwWE9h2vqlhXx3gDLC1iI0Xh6MdlPGTB5JL5OIgTv0nnRfZu2cUpgXfMq3RUWxo1hwXNmmsJB9BGvZM4hi8LIZYDJlomIVJjZYPZEgBqNAUAvwzFAXpsuvfI1dUZ-fLZBhTxT_Qq7keLTQ7Savxcy_IWTqKUl7jheNx45KOzqC3XMg9oEoPnnJWwReOE3c3nK0Cw1tzhWug5wgP_bdMOj5hwZkhu1igWaMArE0E_lGJVernh4zBmAeDaNNtWD6WQivpQ6V1496sLA==) and follow us on [ _Facebook_](https://www.globenewswire.com/Tracker?data=JGA8Ool0BmPSxsotS3m5REvrAbFnX_YO2O59T2oamKb8jklPmrLTrksdfydFuEmGb0M1XN0oUi6RJF5lQg0GBOLoMsAu8POojYXJeJE2KeoDE_BCBNPmiIIIzGa_Ueqzo2opK5AHeGe7KbHHNDJiBEY5zSmbqFVeQ6BQ5CAD0LAzTxm0vrFkvz27q2fflnBBfMEc2sFV8Gcd2kb35CeG5zwQ5kOFJ_T_NPL6hLla0be5eQ7HI-tEY6_RJc2miZor8a5NtmZ-jz7y0hbrX-f86A==), [ _Instagram_](https://www.globenewswire.com/Tracker?data=XTr3QUncNB05T7nTJ4LTNwh2h3h6S0-FozHx_lJYpXwFK9o8ckICnv6iTRg3-LjzjHlG8ZmyfSLkDgz_kTDdyI-JJFNaw8VejKccl-c83h4=), [ _LinkedIn_ ](https://www.globenewswire.com/Tracker?data=3Ft_l1WDu_dUyY_cHafiFScujvrQlnKVaJlvCv-FNo90LqyEP1Y7ZNWlrDIfn3dDV8JpDc3jfI2CuhAVOseAZ1Dmxu73zS3Vjz_qa1zeAKFQ23vYBxNeZY8OzeMWanyFAWr-JLe7FgmyzADbcNbIjXSFcxV5gTOJ5o4QAWEnPqfgge_uJUL0YGGRF69BqKDnmdGZ_KiPIjWfnuHVf3CnUJNbQf_9_fFKkqGZiEpdBEgWRfRb86bmltIZ5TCKQQG63yLfg2ZDaAp6HP5LXXrCH6gxbovoILRoC0FsiciflxJ_BoyITLUHvqKxCWdpOkZa)and [ _Twitter/X_](https://www.globenewswire.com/Tracker?data=CkL_uj0JaAZBbBeDtYGjc4hoBAzdDaUH07hyt2KNz1GAJ3Ji2i2y11Kd1jzesEpPSchlFbjq7TJFJz_vcxbNAAkQM9ZzpiWJwx5pAfJOyA4kwsTfKyiPAiJ0EZivuzcVRfpt5Y-0YTgaQKUybioXxxESywGigcVppHwy8TwZjs0nOSnY5Z7ZkY87LqMbCu77QG_T5qbPINbnGXVWXNtA4imiiRgksJgxc8ZL4EgS6ZHqXlT4wU1CXfBXjZ58sFYX).\n\n![](https://ml.globenewswire.com/media/NzhlODBjYTgtNzA2YS00ODZhLTk0NTEtMTdlNTQyNTZhMDZmLTEyMTI0NDk=/tiny/Praxis-Precision-Medicines-Inc.png)\n\nInvestor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        },
        {
          "title": "Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences",
          "url": "https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-participate-three-upcoming-november",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Press Release \n\n[PDF Version](/node/9711/pdf)\n\n## \n\nPraxis Precision Medicines to Participate in Three Upcoming November Investor Conferences\n\nNovember 6, 2024 at 5:00 PM EST\n\nBOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](https://www.globenewswire.com/Tracker?data=P1OiF-996MLuj7y-SC1gKwVmdCn5_vyivPEpncDb3kqvps6tRPGF3kmL5y3rr_FwLDvMaRBZybpb0ViuYilJKm70f16pEP1UmcHBOjV4Aac=), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.\n\n  * Praxis management will participate in a fireside chat at the **Truist Securities BioPharma Symposium,** taking place in the Lotte New York Palace Hotel in New York, NY on November 7, 2024 at 9:40am ET.\n  * Praxis management will also be participating in a fireside chat at the **Guggenheim Securities Inaugural Healthcare Innovation Conference,** taking place at the InterContinental Boston Hotel in Boston, MA on November 11, 2024 at 1:00pm ET. A live webcast of the fireside chat will be available through this [**link**](https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fguggen%2Fprax%2F1961807&data=05%7C02%7Cnkerrigan%40lifesciadvisors.com%7C2207bc8cc61041109bab08dcf9a8318e%7C65ec683a30ce43d0a6ef2fd46d0f5e8a%7C0%7C0%7C638659748024987649%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=uCAsrebX1h%2FByEqL5ienGWT3jSgy%2BbD0h6qz4%2Bk7PGI%3D&reserved=0)**.**\n  * Praxis management will also be participating in one-on-one meetings at the **Jefferies London Healthcare Conference,** taking place at the Waldorf Hilton Hotel in London, UK on November 20-21, 2024.\n\n\n\nThe Company will also be available for one-on-one meetings at the Truist and Guggenheim conferences. Interested investors should contact their respective corporate access representatives to request meetings.\n\nThe live webcast of Guggenheim fireside chat will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at [www.praxismedicines.com](https://www.globenewswire.com/Tracker?data=dqH9NdS8lhRlU_VnCVdjmwo8YeJaGk2FCkBCF9w86aRnXOPGVk3gGiNmNIB-gxSUPg6ySuQtgBNbwgg2QzU_Kb0X1a_DxIupjctrRN4k9Ws=). Following this event, a replay will be posted, when available, to Praxis’ website on the “[Events and Presentations](https://www.globenewswire.com/Tracker?data=fYRdj-B30juubW0R4edF4sNYYLeP962g4tIV3XL4cKeitgukCawpDIEuR8BFQ55BBMOuSOJpzd2zYsfs6szZJk0-V_Y5E0Kp3pH_l02KyM-zWHTI78goyJxg4Kvjo3h7ivuIbBHyHNigdegGixT7Vg==)” page under the investor section of the website for 90 days.\n\n**About Praxis** Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit [www.praxismedicines.com ](https://www.globenewswire.com/Tracker?data=dqH9NdS8lhRlU_VnCVdjmwo8YeJaGk2FCkBCF9w86aShVoEZBlhg61KGYeruy0tgJDmbZqEIEb1AjWBSeRuFINzG1sTp6cnBZ53IAcIZViwdIVjSYvOyoZWTH-70_usFF3LUSvheybj-aOndnQKgwDFMPNBVz0-WUuKAS2LPUW-N77hmxi4N6n98FVYGGWxeLAwTFNRvHVDgZtslxR-1ml3vsXA2uLZSI9v59IBWUwqKgF7ht7prmshNnz56FHiq7H4qgrFjzUCUMo6et6F_Ew==)and follow us on [Facebook](https://www.globenewswire.com/Tracker?data=zw9pc03CYnsHH9ejdgwHoIXUxTvMxylkKHV1E1lMS3pJFNf98EIoFD2Gy3eNKnWCRgZiFBP0jXBzNstROugIrwIenXb4er00cOTs9JmQQ7rXN2wMq137SLChh01j8iXjWadkqQQ1A0s_Cm9e5I4wHUoEkDrEauTRodz-P2dwil3Q3XSMXL0BDc6Rxn6rw817Tpe6raPQyz6YXuyOTrEQTYPQtgl4Z30vYVCQr-885fAejBVre-F5Bf_mqpVSXng_C5yc6zsLSXRM1hQr9xPcZw==), [LinkedIn ](https://www.globenewswire.com/Tracker?data=_oeyiM2zMUbJ-_SPVD9mCipXMqru6KedWVi9bmRIJZh9eXrOUsXEms9P9n9EpukVzpYMbKZuJqFhXxk_jR9wnb9T4rD8e45Ze8IwU6Kx7By8VWOFuv3wSppvgHgvGgO722iaETi3PVGV8efJFzG78YXWPqnZIWT-0y7Vj1ugSRhBgycM9ihuBzFFKGR4e2h16IChd-MBe-wA9huG1zpQmcMFbVR3K8rN5v5Fx1gfezgeoghaYMngvSz_rSG6r5pQslrK4PYPkBPPYABYBotN9-zohriZ0k43n6c0liKeqeW-9mI4L12IaQ9H5Ry-pSKL)and [Twitter/X](https://www.globenewswire.com/Tracker?data=esxsQo_Ep2pqwTb4f8st3nBeLMD_-FC6fyXqulgFKEjRd5yt8nqM2-hnSwTvJpqkNrM3KhUxna9NIsDX7g-Zirc0y9hJgyTjwCFBHRgTYN_XTrT8FWK2d7KMhalb8oPaNVOv-t7mPlCsyTMYxepSB8fHWMz_s64tYsVrsJsis8kJMzaXvfKN_OLFHfJ-qYuM9baCCoToxch6z413R7Rq_Z4LaAgbsFNIUaFHU16ij3UCdqjxQQbwUcpDQnfrMsML).\n\n![](https://ml.globenewswire.com/media/NmYyNTA2NmQtMzYwOS00OTVhLTllZGMtNDgzYWI0YjRiOGU0LTEyMTI0NDk=/tiny/Praxis-Precision-Medicines-Inc.png)\n\nInvestor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Upcoming & Recent Events",
      "links": [
        {
          "title": "View all events",
          "url": "https://investors.praxismedicines.com/events-and-presentations",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Events & Presentations \n\n##  Presentations \n\nDate | Title  \n---|---  \nNovember 6, 2024 |  [Praxis November 2024 Corporate Presentation](/static-files/9097ab2d-912d-40a7-b1b4-25ab2619a958)  \nSeptember 3, 2024 |  [RELUTRIGINE: EMBOLD Phase 2 Study Topline Results](/static-files/91013dac-4234-4f1e-8128-88e376d27b3b)  \nOctober 2, 2023 |  [R&D Portfolio Overview](/static-files/18b6f8ab-fbf9-4240-8e07-8459687be6e8)  \nMarch 3, 2023 |  [Praxis Precision Medicines Essential1 Topline Results](/static-files/625750d7-3062-48e2-a29c-4b42af61123d)  \n  \n##  Past Events \n\n[Jefferies London Healthcare Conference](/events/event-details/jefferies-london-healthcare-conference)\n\nNovember 20, 2024 at 10:00 AM GMT \n\n[Listen to webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=prax&url=https%3A//wsw.com/webcast/jeff315/prax/1866396)\n\n[Guggenheim Securities Inaugural Healthcare Innovation Conference](/events/event-details/guggenheim-securities-inaugural-healthcare-innovation-conference)\n\nNovember 11, 2024 at 1:00 PM EST \n\n[Listen to webcast](https://wsw.com/webcast/guggen/register.aspx?conf=guggen&page=prax&url=https%3A//wsw.com/webcast/guggen/prax/1961807)\n\n[Praxis Precision Medicines 3Q 2024 Corporate Update](/events/event-details/praxis-precision-medicines-3q-2024-corporate-update)\n\nNovember 6, 2024 at 8:00 AM EST \n\n[Listen to webcast](https://edge.media-server.com/mmc/p/pjfz83z8/)\n\n[Baird Global Healthcare Conference](/events/event-details/baird-global-healthcare-conference)\n\nSeptember 11, 2024 at 2:35 PM EDT \n\nLocation\n\nInterContinental Barclay Hotel, New York, NY\n\n[H.C. Wainwright 26th Annual Global Investment Conference](/events/event-details/hc-wainwright-26th-annual-global-investment-conference)\n\nSeptember 9, 2024 at 12:00 PM EDT \n\n[Listen to webcast](https://journey.ct.events/view/b267f6cc-20af-4d3c-a9b8-4fbef75a9da1)\n\n[Praxis Precision Medicines Corporate Update](/events/event-details/praxis-precision-medicines-corporate-update)\n\nSeptember 3, 2024 at 8:00 AM EDT \n\n[Listen to webcast](https://edge.media-server.com/mmc/p/62z7wwj6/)\n\n[RELUTRIGINE: EMBOLD Phase 2 Study Topline Results](/static-files/91013dac-4234-4f1e-8128-88e376d27b3b \"Relutrigine EMBOLD Readout_Final_v2.pdf\") 1.2 MB\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.praxismedicines.com/financial-information/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -202420232022202120202019201820172016\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | Filing Group | View  \n---|---|---|---|---  \nNovember 19, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-120746) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-120746.pdf](/static-files/51ef8a9d-105e-4d4d-8c27-811b658a388d) [0001104659-24-120746.rtf](/static-files/7d8597f5-416b-4b51-9e0b-27000f783eeb) [0001104659-24-120746.xls](/static-files/d50d2a78-1a25-470f-9882-bd94e4b7f28e) [View HTML](/node/9811/html)  \nNovember 19, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-120748) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-120748.pdf](/static-files/280d7849-1aae-43fb-a44a-84f064808f77) [0001104659-24-120748.rtf](/static-files/8a87faac-36c1-46d9-83ca-d9bb0edbd6c3) [0001104659-24-120748.xls](/static-files/140bc6e1-6223-41c8-926c-4dc6e2d1d692) [View HTML](/node/9816/html)  \nNovember 15, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-119844) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-119844.pdf](/static-files/fad49168-07ec-4c30-9541-3c2f1515a725) [0001104659-24-119844.rtf](/static-files/f3f773d8-0e18-4e69-9c15-56d38312b134) [0001104659-24-119844.xls](/static-files/a0ae7de6-2cb3-4ebb-b7e7-efc6754a1b26) [View HTML](/node/9801/html)  \nNovember 15, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-119843) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-119843.pdf](/static-files/9172e8f2-7220-45f9-9e3f-be744ee82dc5) [0001104659-24-119843.rtf](/static-files/cb0886bd-6ced-41a7-8c7c-7447a5c4d8f6) [0001104659-24-119843.xls](/static-files/2ef591d3-3328-4d53-b671-eb9926816465) [View HTML](/node/9806/html)  \nNovember 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000905148-24-003080) | An amendment to the SC 13G filing |  Other |  [0000905148-24-003080.pdf](/static-files/3d2d8abd-3d8d-4ffb-a3da-ad38b9c67a82) [0000905148-24-003080.rtf](/static-files/08da04dc-0a2c-4095-876d-d1b99ed8ef2a) [0000905148-24-003080.xls](/static-files/fbd7a678-f1f6-4cee-9542-fa42753a997c) [View HTML](/node/9756/html)  \nNovember 14, 2024 | [SC 13G](/sec-filings/sec-filing/sc-13g/0000080255-24-001466) | A statement of beneficial ownership of common stock by certain persons |  Other |  [0000080255-24-001466.pdf](/static-files/974a25c9-6be7-468a-89c6-b87e932e3bc6) [0000080255-24-001466.rtf](/static-files/616f021d-a757-4136-aa98-7262327fe3f4) [View HTML](/node/9761/html)  \nNovember 14, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007842) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001959173-24-007842.pdf](/static-files/31544d69-ae0d-48bf-9c9e-52d542a6632f) [0001959173-24-007842.rtf](/static-files/117104d2-4a64-47f9-927b-afb5935dfa37) [0001959173-24-007842.xls](/static-files/fef23e35-e469-43a4-8df7-bd93f5513f61) [View HTML](/node/9766/html)  \nNovember 14, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-007844) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001959173-24-007844.pdf](/static-files/793c0a46-a6fa-4bf0-ae0d-be455f157b38) [0001959173-24-007844.rtf](/static-files/65308641-3d08-4cf6-bd86-bd1a4d1dc426) [0001959173-24-007844.xls](/static-files/aba25702-ea53-4304-9605-b503481e56db) [View HTML](/node/9771/html)  \nNovember 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001172661-24-005057) | An amendment to the SC 13G filing |  Other |  [0001172661-24-005057.pdf](/static-files/5650ebcc-1a7b-4d38-823c-89101d00afd5) [0001172661-24-005057.rtf](/static-files/1f6437ff-b2b4-406a-bacc-94b4433186bb) [0001172661-24-005057.xls](/static-files/50728dc6-6f8c-4511-b8d9-458445aeb2fd) [View HTML](/node/9776/html)  \nNovember 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001104659-24-119292) | An amendment to the SC 13G filing |  Other |  [0001104659-24-119292.pdf](/static-files/6255344d-4b2e-4f47-97ce-1b8a6be27957) [0001104659-24-119292.rtf](/static-files/ccb6ae79-f58e-4220-ae2d-b5e6a515d634) [0001104659-24-119292.xls](/static-files/16864089-8571-44c5-904f-d73f04a881eb) [View HTML](/node/9781/html)  \n  \nDisplaying 1 - 10 of 355 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://investors.praxismedicines.com/financial-information/annual-reports",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Annual Reports \n\nMore Annual Reports are coming soon. \n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://investors.praxismedicines.com/financial-information/quarterly-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Quarterly Results \n\n[Show all](#)\n\n## 2024\n\nQ3\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-14)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-24-000101)\n\n\n\n\nQ2\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-13)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-24-000088)\n\n\n\n\nQ1\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-12)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-24-000060)\n\n\n\n\n## 2023\n\nQ4\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-11)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001689548-24-000034)\n\n\n\n\nQ3\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-10)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-23-000159)\n\n\n\n\nQ2\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-9)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-23-000128)\n\n\n\n\nQ1\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-8)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-23-000086)\n\n\n\n\n## 2022\n\nQ4\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-7)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001689548-23-000044)\n\n\n\n\nQ3\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-6)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-22-000125)\n\n\n\n\nQ2\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-5)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-22-000111)\n\n\n\n\nQ1\n\n  * [Praxis Precision Medicines 1Q 2022 Corporate Update Call](/events/event-details/praxis-precision-medicines-1q-2022-corporate-update-call)\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-4)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-22-000038)\n\n\n\n\n## 2021\n\nQ4\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-3)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001689548-22-000014)\n\n\n\n\nQ3\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-2)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-21-000094)\n\n\n\n\nQ2\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-1)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-21-000042)\n\n\n\n\nQ1\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-0)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001689548-21-000075)\n\n\n\n\n## 2020\n\nQ4\n\n  * [Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results](/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-reports)\n\n  * [Praxis Precision Medicines 4Q/FY 2020 Corporate Update Call Presentation](/static-files/5d474760-8b33-4d94-91cd-dab0aa1225fd \"Praxis 4Q FY 2020 Corporate Update Call .pdf\") 524.8 KB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001689548-21-000016)\n\n\n\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "FAQs",
          "url": "https://investors.praxismedicines.com/shareholder-services/investor-faqs",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  FAQs \n\n[Show All](#)\n\nIn what year was Praxis founded?\n\nPraxis was incorporated in 2015 and commenced operations in 2016\n\nWhere is Praxis stock listed and what is the ticker symbol?\n\nPraxis is traded on the Nasdaq Global Market under the ticker symbol “PRAX”\n\nWhen was Praxis’ initial public offering (IPO)?\n\nPraxis’ IPO occurred on October 16, 2020 \n\nWhere is Praxis located?\n\nPraxis is headquartered at 99 High Street, 30th Floor, Boston, MA 02110\n\nWhen is Praxis’ fiscal year-end?\n\nPraxis’ fiscal year ends on December 31st\n\nHow can I purchase Praxis stock?\n\nPlease contact a licensed stock broker or use an online trading account to make a stock purchase\n\nWho is Praxis’ transfer agent?\n\nComputerShare Trust Company, N.A. 462 South 4th Street, Suite 1600 Louisville, KY 40202 For help with change of address, transfer of shares, loss of share certificates, consolidation of multiple mailings to one shareholder & estate settlements please call 1-800-736-3001, option 1 (U.S.) or 1-781-575-3100, option 1 (non-U.S.) or email web.queries@computershare.com\n\nWho are Praxis’ independent auditors?\n\nErnst & Young LLP 200 Clarendon St Boston, MA 02116 (617) 266-2000\n\nWho is Praxis’ legal counsel?\n\nLatham & Watkins LLP, 200 Clarendon Street, Boston, MA 02116\n\nHow can I obtain a copy of the Praxis Annual Report or other investor materials?\n\n  * Praxis’ quarterly and annual reports and other SEC filings can be found in the IR section of the corporate website under ‘SEC Filings’\n  * Praxis’ press release archives can be found in the IR section of the corporate website under ‘News Releases’\n  * Praxis’ corporate and other presentations can be found in the IR section of the corporate website under ‘Events & Presentations’\n\n\n\nWhom should I contact if I want to learn more about Praxis?\n\nYou can submit queries to Praxis’ investor relations department by contacting investors@praxismedicines.com\n\nHow can I sign up to receive news release & other company information?\n\nPlease click on ‘[Email Alerts](https://investors.praxismedicines.com/shareholder-services/email-alerts)’ under Investor Resources in the IR section of the corporate website\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.praxismedicines.com/shareholder-services/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Email Alerts \n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nNews  \nWeekly Summary  \n  \nEmail\n\nLeave this field blank\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        },
        {
          "title": "Contact IR",
          "url": "https://investors.praxismedicines.com/shareholder-services/contact-ir",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Contact IR \n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\n  * [Print Page]()\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/shareholder-services/email-alerts)\n  * [Contact IR](/shareholder-services/contact-ir)\n\n\n\n##### Explore More\n\n  * [Overview](/)\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-and-presentations)\n  * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [IRS FORM 8937](/irs-form-8937)\n  * [Corporate Governance](/corporate-governance/governance-overview)\n    * [Documents & Charters ](/corporate-governance/governance-overview)\n    * [Team](https://praxismedicines.com/#team)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Quarterly Results](/financial-information/quarterly-results)\n  * [Investor Resources](/shareholder-services/investor-faqs)\n    * [FAQs](/shareholder-services/investor-faqs)\n    * [Email Alerts](/shareholder-services/email-alerts)\n    * [Contact IR](/shareholder-services/contact-ir)\n\n\n"
        }
      ]
    }
  ]
}